On November 26, 2025, private medical device company Restore Medical announced the appointmentChris Cleary, former Senior Vice President of Corporate Development at Medtronic, serves as the Chairman of the Board.

Mr. Cleary has over thirty years of leadership experience in the healthcare and medical technology fields, with a proven track record in corporate strategy, milestone mergers and acquisitions, and the scaling growth of innovative enterprises.During his tenure at Medtronic, he led several transformative deals, including the company's $50 billion acquisition of Covidien, as well as multiple high-impact transactions in the fields of structural heart disease, neuromodulation, and spine.

Restore Medical is advancing a proprietary minimally invasive therapy aimed at treating patients with heart failure with reduced ejection fraction (HFrEF). With encouraging early clinical results, the company is now preparing to enter the next phase of clinical development and strengthen its leadership team to support global expansion and upcoming U.S. studies. AsCleary's joining the company marks an acceleration in the company's clinical research initiatives.

"Chris has been the driving force behind some of the most significant strategic partnerships in the medical technology field," said Gilad Marom, CEO of Restore Medical. "His extensive experience, strategic vision, and dedication to advancing meaningful medical innovation are crucial for Restore Medical as it expands its clinical programs and advances pivotal studies for its novel transcatheter heart failure therapy. We are thrilled to welcome him to our board of directors."

"I am delighted to join Restore at such a pivotal stage," said Chris Cleary. "The company is leveraging an innovative technology to address a significant unmet need in the field of heart failure, which has the potential to redefine and substantially improve patient outcomes. I look forward to supporting the entire Restore team as they continue to build a strong clinical and commercial foundation."

About Restore Medical

Restore Medical Ltd. is a medical device company dedicated to revolutionizing the treatment of heart failure through its proprietary transcatheter therapies, which aim to improve cardiac function in patients with heart failure with reduced ejection fraction (HFrEF). The company’s mission is to help millions of heart failure patients regain their quality of life by providing safe, effective, and minimally invasive solutions.

Restore Medical, headquartered in Or Yehuda, Israel, has garnered support from leading healthcare investors, including two strategic partners Pitango HealthTech and Peregrine Ventures, as well as the European Innovation Council (EIC) Fund.